RFK Jr. proposes FDA to overlook unproven peptides

Robert F. Kennedy Jr., the current Health Secretary, is pushing for a policy that could ease access to unproven peptide drugs. Despite FDA scientists indicating that these treatments have not been sufficiently studied to ensure their safety and efficacy, an "Interim Access Policy" has been submitted for review by the White House.

The proposal would allow the FDA to exercise "enforcement discretion" over certain peptide drugs, meaning the agency could choose not to enforce existing restrictions. This could pave the way for specialty pharmacies to market these products, which are popular among followers of Kennedy's "Make America Healthy Again" movement.

## Why it matters This decision could have significant implications for public health, as the use of unvalidated treatments may pose risks to patients. Easier access to these peptides could encourage their use without proper medical oversight, potentially leading to unwanted adverse effects.

## What we know It has been confirmed that the FDA has proposed a review of the policy related to peptides, but specific details of this policy have not been publicly disclosed. Additionally, the medical community is concerned about the consequences of allowing access to treatments without sufficient scientific evidence supporting their use.

## What is still unclear It remains unconfirmed when this policy might take effect or what criteria the FDA will use to decide when to apply or not apply restrictions on peptides. The lack of detailed information creates uncertainty regarding the effectiveness and safety of the products that could soon become available.